Patents by Inventor Gustavo Mostoslavsky

Gustavo Mostoslavsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132853
    Abstract: The technology described herein relates to compositions and methods for the generation of a primordial NK/T cell, where the produced NK/T primordial cell can subsequently differentiate into T cells or NK cells at an extremely high efficiency and reproducibility. Other aspects relate to genetically modified iPSC cell lines, and method of their use to generate iPSC-derived NK/T primordial cells with a very high yield and high efficiency.
    Type: Application
    Filed: August 25, 2023
    Publication date: April 25, 2024
    Applicant: BOSTON MEDICAL CENTER CORPORATION
    Inventors: Gustavo MOSTOSLAVSKY, Dar HEINZE
  • Patent number: 11788065
    Abstract: The technology described herein relates to compositions and methods for the generation of a primordial NK/T cell, where the produced NK/T primordial cell can subsequently differentiate into T cells or NK cells at an extremely high efficiency and reproducibility. Other aspects relate to genetically modified iPSC cell lines, and method of their use to generate iPSC-derived NK/T primordial cells with a very high yield and high efficiency.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: October 17, 2023
    Assignee: BOSTON MEDICAL CENTER CORPORATION
    Inventors: Gustavo Mostoslavsky, Dar Heinze
  • Publication number: 20210207100
    Abstract: The technology described herein relates to compositions and methods for the generation of a primordial NK/T cell, where the produced NK/T primordial cell can subsequently differentiate into T cells or NK cells at an extremely high efficiency and reproducibility. Other aspects relate to genetically modified iPSC cell lines, and method of their use to generate iPSC-derived NK/T primordial cells with a very high yield and high efficiency.
    Type: Application
    Filed: December 23, 2020
    Publication date: July 8, 2021
    Applicant: BOSTON MEDICAL CENTER CORPORATION
    Inventors: Gustavo MOSTOSLAVSKY, Dar HEINZE
  • Publication number: 20150004703
    Abstract: The present invention is based on the discovery that a single lentiviral vector expressing multiple individual transcription factor proteins from a single multi-cistronic mRNA can reprogram a fibroblast cell to a stem cell-like cell. These reprogrammed induced pluripotent stem (iPS) cells are pluripotent. Additions of the Cre-LoxP sequences into the single lentiviral vector facilitate excision of the vector after reprogramming in achieved. Addition of a maker gene into the single lentiviral vector facilitates detection of the presence of the vector in an iPS. The invention provides compositions and methods of producing iPS cells using a single multi-cistronic lentiviral vector.
    Type: Application
    Filed: September 15, 2014
    Publication date: January 1, 2015
    Applicant: ONE BOSTON MEDICAL CENTER PLACE
    Inventors: Gustavo Mostoslavsky, Cesar A. Sommer
  • Patent number: 8865467
    Abstract: The present invention is based on the discovery that a single lentiviral vector expressing multiple individual transcription factor proteins from a single multi-cistronic mRNA can reprogram a fibroblast cell to a stem cell-like cell. These reprogrammed induced pluripotent stem (iPS) cells are pluripotent. Additions of the Cre-LoxP sequences into the single lentiviral vector facilitate excision of the vector after reprogramming in achieved. Addition of a maker gene into the single lentiviral vector facilitates detection of the presence of the vector in an iPS. The invention provides compositions and methods of producing iPS cells using a single multi-cistronic lentiviral vector.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: October 21, 2014
    Assignee: Boston Medical Center Corporation
    Inventors: Gustavo Mostoslavsky, Cesar A. Sommer
  • Publication number: 20110236966
    Abstract: The present invention is based on the discovery that a single lentiviral vector expressing multiple individual transcription factor proteins from a single multi-cistronic mRNA can reprogram a fibroblast cell to a stem cell-like cell. These reprogrammed induced pluripotent stem (iPS) cells are pluripotent. Additions of the Cre-LoxP sequences into the single lentiviral vector facilitate excision of the vector after reprogramming in achieved. Addition of a maker gene into the single lentiviral vector facilitates detection of the presence of the vector in an iPS. The invention provides compositions and methods of producing iPS cells using a single multi-cistronic lentiviral vector.
    Type: Application
    Filed: April 6, 2011
    Publication date: September 29, 2011
    Applicant: BOSTON MEDICAL CENTER CORPORATION
    Inventors: Gustavo Mostoslavsky, Cesar A. Sommer